ACP
AERI

Acuta Capital Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Acuta Capital Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50,000
Closed -$1.89M – 79
2016
Q4 		$1.89M Sell
50,000
-230,000
-82% -$8.7M 0.7% 28
2016
Q3 		$10.6M Buy
+280,000
New +$6.17M 3.97% 6

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acuta Capital Partners's AERI Position: Q1 2017 in Review

Acuta Capital Partners sold out of Aerie Pharmaceuticals (AERI) in Q1 2017, closing a stake of 50,000 shares — an estimated $1.89M sold.

Acuta Capital Partners first reported a position in AERI in Q3 2016 and held it in 2 quarters. The position peaked at $10.6M in Q3 2016. 159 funds tracked by Wall St. Rank hold AERI as of Q1 2017.

  • Acuta Capital Partners reported no remaining Aerie Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 50,000 Aerie Pharmaceuticals shares in Q1 2017, an estimated $1.89M.
  • Acuta Capital Partners first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Acuta Capital Partners's Aerie Pharmaceuticals position peaked at $10.6M in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2017.

Based on Acuta Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.